Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1490978 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $15.12Day −1.11%Mkt cap $1.1B1Y −28.6%Off 52W high −34.3%Vol (1Y) 51.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,622 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.4% of sh out |
| Days to cover9.8d |
| 13F net flow (QoQ)−0.52% |
| Top-10 13F concentration65.4% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$254.9M |
| Earnings (TTM)-$103.5M |
| ROE−26.3% |
| Net margin−40.4% |
| ROIC−64.7% |
| Sales growth 3Y12.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−15.4% |
| 1Y−28.6% |
| 3Y−71.1% |
| 5Y−77.9% |
| Since incept. (ann.)−9.4% |
Total return through 2026-07-29 · series begins 2020-02-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)51.1% |
| Ann. volatility (3Y)60.8% |
| Sharpe (1Y)−0.53 |
| Sharpe (3Y)−0.35 |
| Max drawdown (1Y)−50.8% |
| Max drawdown (3Y)−78.8% |
| Beta (3Y vs SPY)2.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 9.7M | $110M | 13.18% | +1.7% |
| GATES FOUNDATION TRUST | 7.0M | $79M | 9.51% | +0.0% |
| Rubric Capital Management LP | 6.0M | $68M | 8.17% | +43.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9M | $44M | 5.26% | new |
| Sumitomo Mitsui Trust Group, Inc. | 3.2M | $36M | 4.34% | −32.3% |
| Amova Asset Management Americas, Inc. | 3.2M | $36M | 4.34% | +13.2% |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.7M | $30M | 3.66% | +17.2% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.7M | $30M | 3.62% | −28.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.81 | — | $58.6M | −1.6% |
| 2025-12-31 | 2026-02-25 | — | — | $87.2M | −1.2% |
| 2025-09-30 | 2025-11-05 | −$0.45 | — | $54.3M | +53.9% |
| 2025-06-30 | 2025-08-06 | −$0.59 | — | $54.8M | +15.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Software 78% · Drug Discovery 22%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
